Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Pancreas. 2010 Nov;39(8):1277–1283. doi: 10.1097/MPA.0b013e3181dd63e1

Figure 1. Vorinostat decreases the viability of pancreatic cancer cells.

Figure 1

Colo357FG, AsPC-1 or MiaPaCa-2 cells (3 × 104/mL) were exposed to different concentrations of vorinostat in a 96-well plate for 48 h and the viability was assessed by XTT assay (Roche). The percent viability was calculated with respect to DMSO-treated controls. Data points = mean ± SE of quadruplicates for each concentration.